NASDAQ:TRVI - Trevi Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.67
  • Forecasted Upside: 265.30 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.92
▲ +0.11 (3.91%)

This chart shows the closing price for TRVI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Trevi Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRVI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRVI

Analyst Price Target is $10.67
▲ +265.30% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Trevi Therapeutics in the last 3 months. The average price target is $10.67, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 265.30% upside from the last price of $2.92.

This chart shows the closing price for TRVI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Trevi Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/4/2022OppenheimerBoost Price Target$12.00N/A
6/29/2022Needham & Company LLCBoost Price TargetBuy$8.00 ➝ $10.00Low
5/24/2022OppenheimerInitiated CoverageOutperform$10.00High
3/29/2022AegisInitiated CoverageBuy$10.00High
11/11/2021Needham & Company LLCLower Price TargetBuy$10.00 ➝ $8.00High
8/13/2021Needham & Company LLCLower Price TargetBuy$12.00 ➝ $10.00High
8/9/2020SVB LeerinkBoost Price TargetOutperform$8.00 ➝ $9.00Medium
8/9/2020BMO Capital MarketsReiterated RatingOutperform ➝ Market Perform$13.00Medium
7/13/2020Needham & Company LLCLower Price TargetBuy$18.00 ➝ $12.00Low
7/13/2020Stifel NicolausLower Price TargetBuy$14.00 ➝ $10.00Low
11/15/2019Needham & Company LLCReiterated RatingBuy$18.00High
6/3/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$14.00High
6/3/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$18.00Medium
6/3/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$15.00Medium
6/3/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$20.00Medium
(Data available from 7/5/2017 forward)

News Sentiment Rating

1.01 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/6/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/5/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/4/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/6/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/5/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/4/2022
  • 9 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/4/2022

Current Sentiment

  • 9 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Trevi Therapeutics logo
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $2.92
Low: $2.68
High: $3.08

50 Day Range

MA: $2.36
Low: $1.94
High: $2.98

52 Week Range

Now: $2.92
Low: $0.46
High: $3.73

Volume

49,118 shs

Average Volume

1,260,946 shs

Market Capitalization

$112.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Trevi Therapeutics?

The following Wall Street research analysts have issued reports on Trevi Therapeutics in the last year: Aegis, Needham & Company LLC, and Oppenheimer Holdings Inc..
View the latest analyst ratings for TRVI.

What is the current price target for Trevi Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Trevi Therapeutics in the last year. Their average twelve-month price target is $10.67, suggesting a possible upside of 265.3%.
View the latest price targets for TRVI.

What is the current consensus analyst rating for Trevi Therapeutics?

Trevi Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TRVI will outperform the market and that investors should add to their positions of Trevi Therapeutics.
View the latest ratings for TRVI.

How do I contact Trevi Therapeutics' investor relations team?

Trevi Therapeutics' physical mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company's listed phone number is (203) 304-2499 and its investor relations email address is [email protected] The official website for Trevi Therapeutics is www.trevitherapeutics.com. Learn More about contacing Trevi Therapeutics investor relations.